BioCentury
ARTICLE | Financial News

Alzheimer's play AC Immune secures $22.1 million

January 10, 2014 1:59 AM UTC

AC Immune S.A. (Lausanne, Switzerland) secured CHF20 million ($22.1 million) in a tranched series D round from undisclosed existing private investors. Also on Thursday, AC Immune announced that it began a Phase I trial to evaluate ACI-35 -- a liposome-based vaccine against phosphorylated microtubule-associated protein tau (MAPT; tau; FTDP-17) -- in patients with mild or moderate Alzheimer's disease (AD). Data are expected in 2015. ...